OMIC vs. CARA, RPID, AXDX, TLIS, TBIO, SEER, SPRB, EVGN, MRM, and FEMY
Should you be buying Singular Genomics Systems stock or one of its competitors? The main competitors of Singular Genomics Systems include Cara Therapeutics (CARA), Rapid Micro Biosystems (RPID), Accelerate Diagnostics (AXDX), Talis Biomedical (TLIS), Telesis Bio (TBIO), Seer (SEER), Spruce Biosciences (SPRB), Evogene (EVGN), MEDIROM Healthcare Technologies (MRM), and Femasys (FEMY). These companies are all part of the "medical" sector.
Singular Genomics Systems (NASDAQ:OMIC) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.
Singular Genomics Systems has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.
Cara Therapeutics received 651 more outperform votes than Singular Genomics Systems when rated by MarketBeat users. Likewise, 74.94% of users gave Cara Therapeutics an outperform vote while only 48.15% of users gave Singular Genomics Systems an outperform vote.
In the previous week, Singular Genomics Systems and Singular Genomics Systems both had 2 articles in the media. Singular Genomics Systems' average media sentiment score of 0.36 beat Cara Therapeutics' score of 0.19 indicating that Singular Genomics Systems is being referred to more favorably in the media.
65.8% of Singular Genomics Systems shares are owned by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are owned by institutional investors. 21.9% of Singular Genomics Systems shares are owned by company insiders. Comparatively, 4.2% of Cara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Cara Therapeutics has a net margin of -565.21% compared to Singular Genomics Systems' net margin of -3,257.30%. Singular Genomics Systems' return on equity of -45.33% beat Cara Therapeutics' return on equity.
Singular Genomics Systems currently has a consensus target price of $0.68, indicating a potential upside of 68.50%. Cara Therapeutics has a consensus target price of $9.75, indicating a potential upside of 1,292.86%. Given Cara Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cara Therapeutics is more favorable than Singular Genomics Systems.
Singular Genomics Systems has higher earnings, but lower revenue than Cara Therapeutics. Cara Therapeutics is trading at a lower price-to-earnings ratio than Singular Genomics Systems, indicating that it is currently the more affordable of the two stocks.
Summary
Singular Genomics Systems beats Cara Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Singular Genomics Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMIC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Singular Genomics Systems Competitors List
Related Companies and Tools
